Skip to main content
Top
Published in: Breast Cancer Research 1/2019

Open Access 01-12-2019 | Letter

Letter to the Editor: A response to Hruska’s case study on molecular breast imaging and the need for true tissue quantification

Authors: Richard M. Fleming, Matthew R. Fleming, Tapan K. Chaudhuri, William C. Dooley, Andrew McKusick

Published in: Breast Cancer Research | Issue 1/2019

Login to get access

Excerpt

We applaud the efforts by Hruska et al. [1] to quantify differences in tissue using molecular breast imaging (MBI) and background parenchymal uptake (BPU); we have discussed the use of such previously [2]. The approach while commendable did not provide diagnostically useful information to differentiate tissue types. This approach, like the utilization of standardized uptake value (SUV), compares differences in background with tissue [3]. As we have already discussed [2, 4, 5] in the literature, this approach is an incorrect model, due to (1) the critical lack of standardization and calibration of nuclear cameras including both SPECT/Planar and PET; (2) the utilization of ratios which are not absolute values and therefore cannot be used to differentiate tissue based upon those issues, issues which are critical to the understanding of tissue differences; and (3) the inability to truly “measure” transitional changes in tissue, which would allow for the determination of actual treatment response on a per patient basis, saving time, money, and lives. …
Literature
2.
go back to reference Fleming RM, Dooley WC. Breast enhanced scintigraphy testing (B.E.S.T.) distinguishes between normal, inflammatory breast changes and breast cancer. A prospective analysis and comparison with mammography. Integr Cancer Ther. 2002;1(3):238–45.CrossRef Fleming RM, Dooley WC. Breast enhanced scintigraphy testing (B.E.S.T.) distinguishes between normal, inflammatory breast changes and breast cancer. A prospective analysis and comparison with mammography. Integr Cancer Ther. 2002;1(3):238–45.CrossRef
3.
go back to reference Keys JW Jr. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36:1836–9. Keys JW Jr. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36:1836–9.
Metadata
Title
Letter to the Editor: A response to Hruska’s case study on molecular breast imaging and the need for true tissue quantification
Authors
Richard M. Fleming
Matthew R. Fleming
Tapan K. Chaudhuri
William C. Dooley
Andrew McKusick
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2019
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-019-1103-6

Other articles of this Issue 1/2019

Breast Cancer Research 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine